Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Significantly increased threshold dose after long-term peanut epicutaneous immunotherapy and daily oral peanut intake.

Fink WR, Capucilli P, Lewis MO, Rooney CB, Brown-Whitehorn TF.

Ann Allergy Asthma Immunol. 2020 Apr;124(4):403-405.e1. doi: 10.1016/j.anai.2020.01.021. Epub 2020 Feb 20. No abstract available.

PMID:
32006703
2.

Efficacy of Epicutaneous Immunotherapy in Children With Milk-Induced Eosinophilic Esophagitis.

Spergel JM, Elci OU, Muir AB, Liacouras CA, Wilkins BJ, Burke D, Lewis MO, Brown-Whitehorn T, Cianferoni A.

Clin Gastroenterol Hepatol. 2020 Feb;18(2):328-336.e7. doi: 10.1016/j.cgh.2019.05.014. Epub 2019 May 14.

PMID:
31100455
3.

Peanut-allergic patient experiences after epicutaneous immunotherapy: peanut consumption and impact on QoL.

Lewis MO, Brown-Whitehorn TF, Cianferoni A, Rooney C, Spergel JM.

Ann Allergy Asthma Immunol. 2019 Jul;123(1):101-103. doi: 10.1016/j.anai.2019.04.006. Epub 2019 Apr 10. No abstract available.

4.

Improving Anaphylaxis Care: The Impact of a Clinical Pathway.

Lee J, Rodio B, Lavelle J, Lewis MO, English R, Hadley S, Molnar J, Jacobstein C, Cianferoni A, Spergel J, Zielinski L, Tsarouhas N, Brown-Whitehorn T.

Pediatrics. 2018 May;141(5). pii: e20171616. doi: 10.1542/peds.2017-1616. Epub 2018 Apr 3.

5.

Omalizumab facilitates rapid oral desensitization for peanut allergy.

MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC.

J Allergy Clin Immunol. 2017 Mar;139(3):873-881.e8. doi: 10.1016/j.jaci.2016.08.010. Epub 2016 Sep 5.

Supplemental Content

Loading ...
Support Center